Comparative Pharmacology
Head-to-head clinical analysis: TECHNESCAN PYP KIT versus TECHNETIUM TC 99M MEBROFENIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECHNESCAN PYP KIT versus TECHNETIUM TC 99M MEBROFENIN.
TECHNESCAN PYP KIT vs TECHNETIUM TC-99M MEBROFENIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m pyrophosphate binds to calcium deposits in damaged myocardial tissue, allowing scintigraphic imaging of acute myocardial infarction.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
For use as a bone imaging agent: 10-20 mCi (370-740 MBq) of technetium Tc-99m pyrophosphate administered intravenously. For cardiac imaging: 15-20 mCi (555-740 MBq) intravenously. Reconstitute vial contents with sodium pertechnetate Tc-99m solution.
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
None Documented
None Documented
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Technetium Tc-99m mebrofenin."
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Technetium Tc-99m mebrofenin."
Terminal half-life: 1.5–2.5 hours (biphasic: initial ~30 min, terminal ~2 h); renal impairment prolongs elimination
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion.
Renal: >90% as unchanged pyrophosphate; biliary/fecal: <5%
Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical